Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
22.68
+1.12 (5.19%)
At close: Jul 30, 2026, 4:00 PM EDT
22.90
+0.22 (0.97%)
After-hours: Jul 30, 2026, 7:34 PM EDT
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Monte Rosa Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $34.83. The average 1-year stock price forecast is 53.57% higher than the current stock price, while the lowest is $29 (+27.87%) and the highest is $40 (+76.37%).
Price Target: $34.83 (+53.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 28, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $35 | Buy | Reiterates | $35 | +54.32% | Jul 13, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $29 | Buy | Reiterates | $29 | +27.87% | Jun 24, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $30 → $31 | Buy | Reiterates | $30 → $31 | +36.68% | May 11, 2026 |
| Wedbush | Wedbush | Buy Maintains $37 | Buy | Maintains | $37 | +63.14% | May 8, 2026 |
Financial Forecast
Revenue This Year
44.48M
from 123.67M
Decreased by -64.04%
Revenue Next Year
58.17M
from 44.48M
Increased by 30.79%
EPS This Year
-1.59
from -0.46
EPS Next Year
-1.81
from -1.59
EPS and Forward PE are based on non-GAAP adjusted numbers.